These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 19538060)

  • 1. The immune system and cancer.
    Loose D; Van de Wiele C
    Cancer Biother Radiopharm; 2009 Jun; 24(3):369-76. PubMed ID: 19538060
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Natural killer cells: the journey from puzzles in biology to treatment of cancer.
    Bodduluru LN; Kasala ER; Madhana RM; Sriram CS
    Cancer Lett; 2015 Feb; 357(2):454-67. PubMed ID: 25511743
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Antitumoral action of interferons and interleukins in combination with radiotherapy. Part I: immunologic basis].
    Herskind C; Fleckenstein K; Lohr J; Li CY; Wenz F; Lohr F
    Strahlenther Onkol; 2004 Apr; 180(4):187-93. PubMed ID: 15057428
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dendritic cells engineered to express the Flt3 ligand stimulate type I immune response, and induce enhanced cytoxic T and natural killer cell cytotoxicities and antitumor immunity.
    Liu Y; Huang H; Chen Z; Zong L; Xiang J
    J Gene Med; 2003 Aug; 5(8):668-80. PubMed ID: 12898636
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor immunology--when a cancer cell meets the immune cells.
    Sheu BC; Hsu SM; Ho HN; Lin RH; Huang SC
    J Formos Med Assoc; 1999 Nov; 98(11):730-5. PubMed ID: 10705688
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Non-specific killer cells in tumor immune response].
    Kumagai K
    Gan To Kagaku Ryoho; 1985 Mar; 12(3 Pt 2):726-33. PubMed ID: 3985642
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Molecular mechanisms of tumor and immune system interaction].
    Berezhnoĭ AE; Gnuchev NV; Georgiev GP; Kozlov AM; Larin SS
    Vopr Onkol; 2008; 54(6):669-83. PubMed ID: 19241839
    [No Abstract]   [Full Text] [Related]  

  • 8. MHC class I antigens, immune surveillance, and tumor immune escape.
    Garcia-Lora A; Algarra I; Garrido F
    J Cell Physiol; 2003 Jun; 195(3):346-55. PubMed ID: 12704644
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Teleost T and NK cell immunity.
    Fischer U; Koppang EO; Nakanishi T
    Fish Shellfish Immunol; 2013 Aug; 35(2):197-206. PubMed ID: 23664867
    [TBL] [Abstract][Full Text] [Related]  

  • 10. T-cell adoptive therapy of tumors: mechanisms of improved therapeutic performance.
    Cohen PA; Peng L; Kjaergaard J; Plautz GE; Finke JH; Koski GK; Czerniecki BJ; Shu S
    Crit Rev Immunol; 2001; 21(1-3):215-48. PubMed ID: 11642606
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Classical and nonclassical HLA class I antigen and NK Cell-activating ligand changes in malignant cells: current challenges and future directions.
    Chang CC; Campoli M; Ferrone S
    Adv Cancer Res; 2005; 93():189-234. PubMed ID: 15797448
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Coexpression of CD40L and CD70 by semiallogenic tumor cells induces anti-tumor immunity.
    Cormary C; Hiver E; Mariamé B; Favre G; Tilkin-Mariamé AF
    Cancer Gene Ther; 2005 Dec; 12(12):963-72. PubMed ID: 15956983
    [TBL] [Abstract][Full Text] [Related]  

  • 13. NK cell activating ligands on human malignant cells: molecular and functional defects and potential clinical relevance.
    Chang CC; Ferrone S
    Semin Cancer Biol; 2006 Oct; 16(5):383-92. PubMed ID: 16931041
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Apoptotic pancreatic tumor cells are superior to cell lysates in promoting cross-priming of cytotoxic T cells and activate NK and gammadelta T cells.
    Schnurr M; Scholz C; Rothenfusser S; Galambos P; Dauer M; Röbe J; Endres S; Eigler A
    Cancer Res; 2002 Apr; 62(8):2347-52. PubMed ID: 11956095
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The dual-functional capability of cytokine-induced killer cells and application in tumor immunology.
    Zhang Q; Liu XY; Zhang T; Zhang XF; Zhao L; Long F; Liu ZK; Wang EH
    Hum Immunol; 2015 May; 76(5):385-91. PubMed ID: 25305457
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Downregulation of innate and acquired antitumor immunity by bystander gammadelta and alphabeta T lymphocytes with Th2 or Tr1 cytokine profiles.
    Seo N; Tokura Y
    J Interferon Cytokine Res; 1999 Jun; 19(6):555-61. PubMed ID: 10433355
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Antitumor immunity and cellular cancer therapies].
    Catros-Quemener V; Bouet F; Genetet N
    Med Sci (Paris); 2003 Jan; 19(1):43-53. PubMed ID: 12836191
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The 'T-cell-ness' of NK cells: unexpected similarities between NK cells and T cells.
    Narni-Mancinelli E; Vivier E; Kerdiles YM
    Int Immunol; 2011 Jul; 23(7):427-31. PubMed ID: 21665959
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The dual effects of interleukin-18 in tumor progression.
    Park S; Cheon S; Cho D
    Cell Mol Immunol; 2007 Oct; 4(5):329-35. PubMed ID: 17976312
    [TBL] [Abstract][Full Text] [Related]  

  • 20. NK cells and T cells: mirror images?
    Versteeg R
    Immunol Today; 1992 Jul; 13(7):244-7. PubMed ID: 1388649
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.